Understand the source comparison
GLP-1 Agonists vs Tesofensine: Hormonal Satiety vs Neurotransmitter Modulation
GLP-1 receptor agonists. Semaglutide, tirzepatide, liraglutide. Work by mimicking glucagon-like peptide-1, an incretin hormone released by intestinal L-cells in response to food intake. These compounds bind to GLP-1 receptors in the hypothalamus to signal sati
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 receptor agonists. Semaglutide, tirzepatide, liraglutide. Work by mimicking glucagon-like peptide-1, an incretin hormone released by intestinal L-cells in response to food intake. These compounds bind to GLP-1 receptors in the hypothalamus to signal satiety, slow gastric emptying to extend postprandial fullness, and enhance insulin secretion in a glucose-dependent manner. The appetite suppression is indirect: by delaying gastric emptying, food stays in the stomach longer, mechanoreceptors signal fullness, and ghrelin (the hunger hormone) secretion is delayed. Clinical trials show semaglutide 2.4mg weekly produces 14.9% mean body weight reduction at 68 weeks (STEP-1), with gastrointestinal side effects (nausea, vomiting) occurring in 30–45% of participants during dose escalation.
- Tesofensine bypasses the gut entirely. It acts on dopamine and norepinephrine pathways in the hypothalamus. The same neural circuits that stimulants like amphetamine target, but with lower abuse potential due to its relatively balanced monoamine profile. The Lancet Phase II trial showed 12.8% mean weight reduction at 36 weeks on 0.5mg daily. Comparable magnitude to semaglutide but in half the time. However, side effects differ markedly: tesofensine's most common adverse events are dry mouth (40%), insomnia (28%), and increased heart rate (mean +5 bpm at 0.5mg dose). All stimulant-mediated effects absent in GLP-1 protocols.
- Stacking tesofensine with GLP-1 agonists creates additive appetite suppression through complementary pathways: peripheral hormonal signaling (GLP-1) plus central neurotransmitter modulation (tesofensine). Our team has reviewed this across protocols in research settings. The pattern is consistent: the combination produces greater total weight loss than either compound alone, but side effect burden increases. Particularly nausea from semaglutide and stimulant effects from tesofensine. Dosing adjustments are mandatory: lower doses of each compound when stacked compared to monotherapy.